ASX ANNOUNCEMENT **6 February 2025**

Investor Webinar

Melbourne, Australia; 6 February 2025: Cynata Therapeutics Limited (ASX: **"CYP"**, **"Cynata"**, or the **"Company"**), a clinical-stage biotechnology company specialising in cell therapeutics, reminds shareholders that CEO and Managing Director, Dr Kilian Kelly, will host an investor webinar today, Thursday 6 February 2025 at 10:30am AEDT.

Attendees are required to register in advance for the webinar – using the following link:
https://us02web.zoom.us/webinar/register/WN_X-L7ioGETN6cOcf-D0fQ1Q

Upon registration, attendees will receive a link to access the webinar.

A copy of the presentation to be delivered during the webinar is attached to this announcement.

-ENDS-

Authorised for release by Dr Kilian Kelly, CEO & Managing Director

CONTACTS: Dr Kilian Kelly, CEO & MD, Cynata Therapeutics, +61 (03) 7067 6940, kilian.kelly@cynata.com
Lauren Nowak, Media Contact, +61 (0)400 434 299, lauren@littlebigdeal.au

About Cynata Therapeutics (ASX: CYP)
Cynata Therapeutics Limited (ASX: CYP) is an Australian clinical-stage stem cell and regenerative medicine company focused on the development of therapies based on Cymerus™, a proprietary therapeutic stem cell platform technology. Cymerus™ overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

Cynata has demonstrated positive safety and efficacy data for its Cymerus™ product candidates CYP-001 and CYP-006TK, in Phase 1 clinical trials in steroid-resistant acute graft versus host disease (GvHD), and diabetic foot ulcers (DFU), respectively. Further clinical trials are now ongoing: a Phase 2 trial of CYP-001 in GvHD under a cleared US FDA IND; a Phase 1/2 trial of CYP-001 in patients undergoing kidney transplant; and a Phase 3 trial of CYP-004 in osteoarthritis. In addition, Cynata has demonstrated utility of its Cymerus™ technology in preclinical models of numerous other diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome (ARDS) and cytokine release syndrome.

Cynata Therapeutics encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.

cynata therapeutics



A Clinical Stage Company Pioneering the Next Generation of Cellular Therapies

Investor Webinar

6 February 2025

Important information

Summary information

This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries (**CYP**, or **Cynata**) which is current as at 5 February 2025. This Presentation should be read in conjunction with CYP's other periodic and continuous disclosure information lodged with the Australian Securities Exchange (**ASX**), which are available at www.asx.com.au.

Not an offer

This Presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with the ASIC) or any other law. This Presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not investment advice

This Presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation by CYP or its advisers to acquire CYP securities. This Presentation has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. CYP is not licensed to provide financial product advice in respect of CYP securities.

Investment risk and past performance

An investment in CYP securities is subject to known and unknown risks, some of which are beyond the control of CYP and its directors. CYP does not guarantee any particular rate of return or performance of CYP. Past performance cannot be relied upon as an indicator of (and provides no guidance as to) future CYP performance including future share price performance.

Financial data

All financial information in this Presentation is in Australian currency (A$) unless otherwise stated. This Presentation contains historical financial information based on financial information that has been disclosed to the ASX. Any discrepancies between totals and sums of components in tables and figures in this Presentation are due to rounding.

Forward-looking statements

This Presentation contains certain 'forward looking statements', which can generally be identified by the use of forward looking words such as 'expect', 'anticipate', 'likely', 'intend', 'should', 'could', 'may', 'predict', 'plan', 'propose', 'will', 'believe', 'forecast', 'estimate', 'target', 'outlook', 'guidance', 'potential' and other similar expressions. The forward looking statements contained in this Presentation are not guarantees or predictions of future performance and involve known and unknown risks and uncertainties and other factors, many of which are beyond the control of CYP, its directors and management, and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There can be no assurance that actual outcomes will not differ materially from these forward looking statements. A number of important factors could cause actual results or performance to differ materially from the forward looking statements. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation. The forward looking statements are based on information available to CYP as at the date of this Presentation. Except as required by law or regulation (including the ASX Listing Rules), CYP and its directors, officers, employees, advisers, agents and intermediaries undertake no obligation to provide any additional or updated information whether as a result of new information, future events or results or otherwise. You are strongly cautioned not to place undue reliance on forward-looking statements.

Industry and Market data

Certain market and industry data used in connection with this Presentation may have been obtained from research, surveys or studies conducted by third parties, including industry or general publications. Neither CYP nor its representatives have independently verified any such market or industry data provided by third parties or industry or general publications.

Disclaimer

To the maximum extent permitted by law, CYP and its advisers, affiliates, related bodies corporate, directors, officers, partners, employees and agents (**Related Persons**) exclude and disclaim all liability, including without limitation for negligence, for any expenses, losses, damages or costs arising from this Presentation or reliance on anything contained in or omitted from it. To the maximum extent permitted by law, CYP and its Related Persons make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this Presentation and disclaim any obligation or undertaking to release any update or revision to the information in this Presentation to reflect any change in expectations or assumptions. Statements made in this Presentation are made only as at the date of this Presentation. The information in this Presentation remains subject to change without notice.

Corporate overview

Cynata is an ASX-listed company (ticker **CYP**), founded to commercialise the novel iPSC-based Cymerus™ platform, for the scalable and consistent production of mesenchymal stem cell (MSC)-based therapies

Financial information

Share price (5 February 2025)	A$0.245
Shares on issue	~225m
Market capitalisation	~A$55m

Share price – calendar year 2024

Largest shareholders

BioScience Managers — **10.5%**

Bioscience Managers is an international healthcare investment firm headquarter in Melbourne that finances and enables innovative science and technology with the potential to transform healthcare.

Fidelity INTERNATIONAL — **10%**

Fidelity International is a world leading investment and asset management firm, responsible for total client assets of >US$750 billion, from clients across Asia Pacific, Europe, the Middle East, South America and Canada.

FUJIFILM — **3.6%**

Fujifilm is a Japanese multinational conglomerate. Cynata has a strategic manufacturing partnership with Fujifilm.

Top 20 shareholders hold ~47% of shares on issue

Target indications

Indication		Trial phase	Upcoming catalysts*	Market opportunity
Acute Graft vs Host Disease (aGvHD) **FDA Orphan Designation**	Cynata Funded & Managed	**Phase 2 ongoing**	**Enrolment completion – H1 2025** **Results – H2 2025**	US$600m[1]
Diabetic Foot Ulcers (DFU)	Cynata Funded & Managed	**Phase 1 complete**	**Results released Dec 2024**	US$9.6bn[2]
Osteoarthritis (OA) *(managed by USYD, **funded by NHMRC**)*	Partner Funded & Managed	**Phase 3 ongoing** (enrolment complete)	**Results – H1 2026**	US$11.6bn[3]
Kidney Transplantation *(managed and **funded by LUMC**)*	Partner Funded & Managed	**Phase 1/2 ongoing**	**Results (Cohort 1) – H1 2025**	US$5.9bn[4]

Note: Cynata retains commercial rights for both of the partner funded & managed programs

cynata therapeutics

1. Global Graft versus Host Disease Market 2019-2029 (Reflects forecast market in 2026); 2. Zion Market Research, 2019 (represents global treatment market in 2025); 3. Persistence Market Research 2018 research report: "Osteoarthritis Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025) (Reflect OA market by 2025); 4. Organ Transplant Immunosuppressant Drugs Market in 2026, Grand View Research, Inc.,2019
USYD = University of Sydney; NHMRC = National Health and Medical Research Council; LUMC = Leiden University Medical Center
* Timing of events is approximate, based on the Company's information as at the date of this presentation, and subject to change. Timing refers to calendar years.

December 2024 Quarter – Key Highlights

- **Phase 1 clinical trial in diabetic foot ulcer (DFU) completed**
  - CYP-006TK demonstrated to be safe and well tolerated, with positive efficacy data indicating substantially improved wound healing for CYP-006TK compared to the standard of care control group
- **Phase 2 clinical trial in acute graft-versus-host disease (aGvHD)**
  - recruitment now >40% complete, with the rate of recruitment substantially accelerating in recent months; primary results still anticipated late 2025
- **Phase 1 clinical trial in kidney transplantation**
  - first patient treated; completion of first cohort anticipated in Q1 2025
- **Phase 3 clinical trial in osteoarthritis**
  - all patients have completed study treatment; results expected in 1H 2026
- **Balance sheet strengthened**
  - $1.88m R&D Tax Incentive rebate
  - $8.10m institutional placement
- **Strong cash balance**
  - $10.51m at end of quarter with forecast cash runway into mid 2026

CYP-006TK for Diabetic Foot Ulcers



Diabetic foot ulcers (DFU)

- Open sore or wound that develops in patients with diabetes
- Very difficult to heal, which can lead to serious complications such as serious infection
- 20% of patients who develop DFU will require an amputation[1]
- Multi-disciplinary team can be required to treat: GP, endocrinologist, podiatrist, wound care nurse, vascular surgeon and infectious disease specialist
- Cost to treat DFU in the US can exceed US$60,000 per patient (depending on severity)[2]
- Annual costs to US public and private payers estimated to be US$9 – 13 billion per year[2]



WIfI = Wound, Ischemia, and foot Infection[3]

Diabetes is the **fastest growing** public health concern worldwide[4]

~38 million Americans have diabetes[5]

Up to 34% of those with diabetes will develop a foot ulcer[1]

20% of patients with DFU will require **amputation** of the foot or limb[1]

150,000+ amputations **per year** in the US due to **DFU**[6]

Estimated costs to US public and private payers **US$9–13 billion** per year[2]

1. McDermott et al. Diabetes Care. 46:209–221 (2023).
2. Raghav et al. Ther Adv Endocrinol Metab. 9(1) 29-31 (2018).
3. Hicks et al. J Vasc Surg. 67:1455-62 (2018).
4. Hossain et al. Health Sci Rep. 7(3):e2004 (2024).
5. American Diabetes Association: https://diabetes.org/about-diabetes/statistics/about-diabetes
6. American Diabetes Association: https://diabetes.org/advocacy/amputation-prevention-alliance

Cynata's MSC product for DFU

- Cynata has developed a proprietary wound dressing using MSCs ("CYP-006TK")
- CYP-006TK utilises a proprietary surface-coating, optimised for the delivery of MSCs directly to the wound



DFU | Phase 1 clinical trial

Indication	Non-healing diabetic foot ulcers (DFU)
Product	CYP-006TK (novel silicone dressing seeded with Cymerus™ iPSC-derived MSCs)
Study Design	• Randomised controlled trial in ~30 adults • Patients randomised to receive either standard of care (SOC) or CYP-006TK for 4 weeks, followed by SOC • SOC treatment = current best practice as determined by investigator (e.g. conventional wound dressings etc) • Primary objective was safety; efficacy measures included wound healing, pain and quality of life
Study Conduct	• Clinical sites in Australia (Adelaide and Perth) • Patient enrolment complete (April 2024) • All patient visits complete (September 2024)
Results	**Final results released in December 2024**

cynata therapeutics

For further information: https://clinicaltrials.gov/study/NCT05165628

Safety and tolerability

Primary Objective

Phase 1 clinical trial of CYP-006TK in DFU **successfully achieved** its primary objective:

– safe and well-tolerated

– no participants withdrew from the trial due to adverse events

– no suspected serious adverse reactions were reported

Change in wound surface area



Reduction in wound size (Improvement)

Increase in wound size (Deterioration)



CYP-006TK

- Substantial mean reduction (improvement) in wound surface area at both 12 & 24 weeks, in both mm^2 and percentage terms

Standard of Care

- Mean increase (deterioration) in wound surface area at both 12 & 24 weeks, in mm^2 terms
- Increase in mm^2 terms combined with moderate reduction in percentage terms indicates that **larger wounds were less likely to heal**

cynata therapeutics

Larger wounds* (measuring >200 mm²)



Reduction in wound size (Improvement)

Increase in wound size (Deterioration)



CYP-006TK

- Mean reduction in wound surface area was similar in larger wounds to when all wounds were included
- Substantial improvement in large wounds is especially encouraging as larger DFU are more likely to lead to an amputation[1]

Standard of Care

- Extent of mean increase (deterioration) was greater in larger wounds than when all wounds were included
- Mean change by percentage was markedly worse in larger wounds than in all wounds

* A total of 19 participants had wounds measuring <200 mm² at baseline (nine in the CYP-006TK group; ten in the control group)

1. Pickwell K, et al. Diabetes Care. 2015;38(5):852-7.

cynata therapeutics

Ongoing clinical trials - leveraging the unique potential of Cymerus MSCs



aGvHD | Phase 2 clinical trial

Indication	High risk acute graft versus host disease (aGvHD)[1]
Product	CYP-001 (Cymerus™ iPSC-derived MSCs for intravenous infusion)
Study Design	• Randomised, double-blind, placebo-controlled trial • ~60 adults (steroids + CYP-001 vs steroids + placebo) • Primary objective is to assess efficacy of CYP-001 based on Overall Response Rate at Day 28
Study Conduct	• Conducted under IND from US FDA • Clinical sites in USA, Europe and Australia • First patient enrolled in March 2024; enrolment >40% complete[2] • Aiming to complete patient enrolment in H1 2025
Results	Results anticipated in H2 2025 (primary evaluation)

cynata therapeutics

1. Trial is recruiting patients with High Risk newly diagnosed aGvHD (risk assessed based on refined Minnesota criteria), which means patients are not yet eligible to receive ruxolitinib. This is earlier in treatment pathway than completed Phase 1 trial, which was conducted in patients with steroid-resistant aGvHD. For further information see: https://clinicaltrials.gov/study/NCT05643638
2. As of December 2024 Quarterly Activity Report, released to ASX on 30 January 2025

OA | Phase 3 clinical trial

Indication	Osteoarthritis (OA) of the knee (Kellgren-Lawrence Grade 2-3)
Product	CYP-004 (Cymerus™ iPSC-derived MSCs for intra-articular injection)
Study Design	• Randomised, double-blind placebo-controlled trial in ~320 adults[1] • Each participant receives 3 injections over 12 months; follow-up of 24 months from first dose • Co-primary endpoints are reduction of knee symptoms and measure of cartilage loss
Study Conduct	• Trial conducted by University of Sydney, funded by Australian Government NHMRC grant, while Cynata retains commercial rights, with clinical centres in Sydney and Hobart • Patient enrolment complete (November 2023) • Patient treatment complete (November 2024) • Last patient last visit expected ~November 2025
Results	• Results anticipated in H1 2026

cynata therapeutics

1. Clinical trial entitled Stem Cells as a symptom – and strUcture-modifying Treatment for medial tibiofemoral OsteoaRthritis: a randomised placebo-controlled trial (SCUlpTOR). NHMRC: National Health and Medical Research Council
For further information: https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=379726&isReview=true

Kidney transplant | Phase 1/2 clinical trial

Indication	Prevention of kidney transplant rejection
Product	CYP-001 (Cymerus™ iPSC-derived MSCs for intravenous infusion)
Study Design	• ~16 patients to receive CYP-001 after kidney transplantation: cohort 1 (n=3); cohort 2 (n=3); cohort 3 (n=10) • Trial will evaluate safety (all cohorts) and efficacy of MSCs in facilitating reduction of calcineurin inhibitors (anti-rejection medication; Cohort 3)
Study Conduct	• Trial conducted and funded by Leiden University Medical Center (LUMC), Netherlands, while Cynata retains commercial rights • Patient enrolment commenced in Q4 2024, with first patient treatment completed in Dec 2024
Results	Outcome of Cohort 1 anticipated in H1 2025

Outlook and commercial potential



Industry connections

- Upcoming catalysts will accelerate and broaden partnering discussions
- We attend leading conferences in our sector, to tell our story and open new discussions
- Following on from multiple events earlier this year, selected key events going forward include:

BIOTECH SHOWCASE™	JP Morgan BioWeek/Biotech Showcase San Francisco, January 2025	Company presentation and partnering meetings
advanced THERAPIES	Advanced Therapies Congress London, March 2025	Company presentation and partnering meetings
Bio International Convention	BIO International Boston, June 2025	Partnering meetings
BioJapan / RM Regenerative Medicine Japan	BIO Japan, RM Japan Yokohama, October 2025	Partnering meetings

- We will also attend further key events in the sector (ARM, ISCT, ISSCR) and in the regions

Important new publication

npj | regenerative medicine

Article

Published in partnership with the Australian Regenerative Medicine Institute

https://doi.org/10.1038/s41536-024-00382-y

Proteomic profiling of iPSC and tissue-derived MSC secretomes reveal a global signature of inflammatory licensing

Check for updates

Margeaux Hodgson-Garms[1,2], Matthew J. Moore[1], Mikaël M. Martino[3,4], Kilian Kelly[2] & Jessica E. Frith[1,3]

Much of the therapeutic potential of mesenchymal stromal cells (MSCs) is underpinned by their secretome which varies significantly with source, donor and microenvironmental cues. Understanding these differences is essential to define the mechanisms of MSC-based tissue repair and optimise cell therapies. This study analysed the secretomes of bone-marrow (BM.MSCs), umbilical-cord (UC.MSCs), adipose-tissue (AT.MSCs) and clinical/commercial-grade induced pluripotent stem cell-derived MSCs (iMSCs), under resting and inflammatory licenced conditions. iMSCs recapitulated the inflammatory licensing process, validating their comparability to tissue-derived MSCs. Overall, resting secretomes were defined by extracellular matrix (ECM) and pro-regenerative proteins, while licensed secretomes were enriched in chemotactic and immunomodulatory proteins. iMSC and UC.MSC secretomes contained proteins indicating proliferative potential and telomere maintenance, whereas adult tissue-derived secretomes contained fibrotic and ECM-related proteins. The data and findings from this study will inform the optimum MSC source for particular applications and underpin further development of MSC therapies.

Upcoming catalysts*

DFU results announced Dec 2024; results from THREE further trials expected by 1H 2026



* Timing of events is approximate, based on the Company's information as at the date of this presentation, and subject to change

Contact Us

Cynata Therapeutics Limited
Level 3, 100 Cubitt Street
Cremorne
Victoria 3121
Australia

info@cynata.com

www.cynata.com

cynatatherapeutics

@cynatastemcells

cynata-therapeutics